Abstract:B-precursor acute lymphoblastic leukemia (B-ALL) is the leading cause of cancer-related deaths in children and commonly has a poor outcome in adults. Gene profiling and exome sequencing of high-risk ALLs led to the recent identification of the Philadelphia chromosome (Ph)-like ALL subtype. These leukemias have gene expression profiles similar to BCR-ABL1-positive (Ph+) ALL, but lack a BCR-ABL1 rearrangement, and often result in poor outcomes. Many Ph-like ALL-associated mutations identified to date are known or predicted to activate oncogenic cytokine receptor signaling pathways, particularly those associated with JAK. The lymphocyte adaptor protein LNK (also called SH2B3) has emerged as a powerful negative regulator of cytokine-mediated JAK2 signaling in hematopoietic stem cells (HSCs). Loss-of-function LNK mutations and deletions have recently been described in B-ALL, and germline loss of LNK contributes to pediatric ALL development. However, the mechanisms by which LNK alterations impact leukemogenesis remain poorly understood. Here we show that LNK synergizes with TP53 and INK4a in suppressing B-ALL development in mice. Tp53-/-Lnk-/- mice developed highly aggressive and transplantable B-ALL with 100% penetrance in contrast to T-lymphoma or sarcoma development observed in Tp53-/- mice. Importantly, gene expression profiles of Tp53-/-Lnk-/- B-ALL blasts were similar to those of human Ph-like B-ALLs, validating the relevance of this model for preclinical studies. Tp53-/-Lnk-/- pro-B progenitors initiated B-ALL in the transplanted recipients, and Lnk loss-of-heterozygosity (LOH) was found exclusively in B-ALL cells from Tp53-/-Lnk+/- mice, but not in HSCs, common lymphoid progenitors, or cells of myeloid/T cell lineages, attesting that LNK is a bona fide tumor suppressor in the committed B-cell precursors. Mechanistically, we found that pre-leukemic Lnk-/-Tp53-/- pro-B progenitors were hypersensitive to IL-7 and showed markedly enhanced self-renewal ability in vitro and in vivo. Our genetic studies revealed that LNK controls normal B cell and B-ALL development independently of its effects on HSCs and specifically regulates pro-B cell homeostasis. A novel phosphoflow cytometry approach in freshly isolated BM cells that combines the surface marker B220, intracellular mu-heavy chain detection, and phospho-specific antibodies enabled separation of subpopulations of B progenitors with distinct IL-7 responsiveness. Using this approach, we demonstrated that LNK deficiency potentiated STAT5 activation in response to IL-7 in pre-leukemic pro-B cells. Of note, Lnk-/-p53-/- leukemic blasts with elevated pSTAT5, were less sensitive to JAK inhibitors than pre-leukemic B progenitors, in part due to constitutive activation of MAPK and AKT/mTOR pathways. Our results invoke the targeting of these pathways as novel therapeutic approaches in B-ALL. In sum, we have developed a novel B-ALL mouse model suitable for preclinical studies aimed at further deciphering the pathogenic mechanisms underlying this disease and exploring new therapeutic strategies.

Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes

Klf4 Acts As A Tumor Suppressor In T-Acute Lymphoblastic Leukemia And Negatively Regulates Human T Cell Development And Homeostasis

KLF4 Downregulates Htert Expression and Telomerase Activity to Inhibit Lung Carcinoma Growth.

Putative Tumor-Suppressive Function of Krüppel-Like Factor 4 in Primary Lung Carcinoma

UTX Inhibition As Selective Epigenetic Therapy Against TAL1-driven T-cell Acute Lymphoblastic Leukemia

Klf4 Translation Level is Associated with Differentiation Stage of Different Pediatric Leukemias in Both Cell Lines and Primary Samples

Krüppel-like Factor 4 Contributes to the Pathogenesis of Mantle Cell Lymphoma.

BACH2-mediated CD28 and CD40LG axes contribute to pathogenesis and progression of T-cell lymphoblastic leukemia

Regulatory Network Analysis Reveals the Oncogenesis Roles of Feed-Forward Loops and Therapeutic Target in T-cell Acute Lymphoblastic Leukemia.

SIRT1 Regulates the Phosphorylation and Degradation of P27 by Deacetylating CDK2 to Promote T-cell Acute Lymphoblastic Leukemia Progression.

Activation of CaMKIIγ Potentiates T-cell Acute Lymphoblastic Leukemia Leukemogenesis Via Phosphorylating FOXO3a

RUNX1 Inhibits Proliferation and Induces Apoptosis of T(8;21) Leukemia Cells Via KLF4-mediated Transactivation of P57

KLF4α Up-regulation Promotes Cell Cycle Progression and Reduces Survival Time of Patients with Pancreatic Cancer

Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia

Aberrant Expression of SALL4 in Acute B Cell Lymphoblastic Leukemia: Mechanism, Function, and Implication for a Potential Novel Therapeutic Target

Lnk (Sh2b3) Synergizes With Tp53 In Suppressing B-Precursor Acute Lymphoblastic Leukemia Through Il-7 Receptor Signaling

KLF4 transcription factor in tumorigenesis

High Crlf2 Expression Associates with Ikzf1 Dysfunction in Adult Acute Lymphoblastic Leukemia Without Crlf2 Rearrangement

Notch1 Signaling is Involved in Regulating Foxp3 Expression in T-ALL.

Enhancer looping protein LDB1 modulates MYB expression in T-ALL cell lines in vitro by cooperating with master transcription factors

YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia